Cargando…
Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
Background: Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis, and bleeding events. Factors associate...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465018/ https://www.ncbi.nlm.nih.gov/pubmed/32824667 http://dx.doi.org/10.3390/jcm9082664 |
_version_ | 1783577495153410048 |
---|---|
author | Ngo, Doan T. M. Williams, Trent Horder, Sophie Kritharides, Leonard Vardy, Janette Mandaliya, Hiren Nordman, Ina I. C. Lynam, James Bonaventura, Tony Sverdlov, Aaron L. |
author_facet | Ngo, Doan T. M. Williams, Trent Horder, Sophie Kritharides, Leonard Vardy, Janette Mandaliya, Hiren Nordman, Ina I. C. Lynam, James Bonaventura, Tony Sverdlov, Aaron L. |
author_sort | Ngo, Doan T. M. |
collection | PubMed |
description | Background: Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis, and bleeding events. Factors associated with increased risks of adverse cardiovascular effects with bevacizumab have not been intensively studied. In this study, we determined factors associated with hospital admissions due to cardiovascular complications in patients who received bevacizumab for cancer treatment. Methods and Results: We retrospectively collected data for all patients treated with bevacizumab between the 1st January 2016 and the 31st December 2017 at the Hunter New England Local Health District. Patients’ characteristics and their medical history were obtained from hospital electronic medical records. Outcome data were sourced from the Institutional Cardiac and Stroke Outcomes Unit database. A total of n = 230 patients (mean age 65, males n = 124 (53.9%)) were treated with bevacizumab during the study period. N = 28 patients were admitted to hospital for a major cardiovascular-related event. Higher total treatment dose (p < 0.05), concomitant hypertension (p = 0.005), diabetes (p = 0.04), atrial fibrillation (p = 0.03), and lack of use of statin therapy (p = 0.03) were key contributors to hospital admission. Conclusions: Results of our study highlight the fact that patients with concomitant baseline cardiovascular disease/risk factors are at an increased risk of cardiovascular hospitalization related to bevacizumab treatment. Careful baseline cardiovascular assessment may be an essential step to minimize cardiovascular complications. |
format | Online Article Text |
id | pubmed-7465018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74650182020-09-04 Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab Ngo, Doan T. M. Williams, Trent Horder, Sophie Kritharides, Leonard Vardy, Janette Mandaliya, Hiren Nordman, Ina I. C. Lynam, James Bonaventura, Tony Sverdlov, Aaron L. J Clin Med Article Background: Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis, and bleeding events. Factors associated with increased risks of adverse cardiovascular effects with bevacizumab have not been intensively studied. In this study, we determined factors associated with hospital admissions due to cardiovascular complications in patients who received bevacizumab for cancer treatment. Methods and Results: We retrospectively collected data for all patients treated with bevacizumab between the 1st January 2016 and the 31st December 2017 at the Hunter New England Local Health District. Patients’ characteristics and their medical history were obtained from hospital electronic medical records. Outcome data were sourced from the Institutional Cardiac and Stroke Outcomes Unit database. A total of n = 230 patients (mean age 65, males n = 124 (53.9%)) were treated with bevacizumab during the study period. N = 28 patients were admitted to hospital for a major cardiovascular-related event. Higher total treatment dose (p < 0.05), concomitant hypertension (p = 0.005), diabetes (p = 0.04), atrial fibrillation (p = 0.03), and lack of use of statin therapy (p = 0.03) were key contributors to hospital admission. Conclusions: Results of our study highlight the fact that patients with concomitant baseline cardiovascular disease/risk factors are at an increased risk of cardiovascular hospitalization related to bevacizumab treatment. Careful baseline cardiovascular assessment may be an essential step to minimize cardiovascular complications. MDPI 2020-08-18 /pmc/articles/PMC7465018/ /pubmed/32824667 http://dx.doi.org/10.3390/jcm9082664 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ngo, Doan T. M. Williams, Trent Horder, Sophie Kritharides, Leonard Vardy, Janette Mandaliya, Hiren Nordman, Ina I. C. Lynam, James Bonaventura, Tony Sverdlov, Aaron L. Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab |
title | Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab |
title_full | Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab |
title_fullStr | Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab |
title_full_unstemmed | Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab |
title_short | Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab |
title_sort | factors associated with adverse cardiovascular events in cancer patients treated with bevacizumab |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465018/ https://www.ncbi.nlm.nih.gov/pubmed/32824667 http://dx.doi.org/10.3390/jcm9082664 |
work_keys_str_mv | AT ngodoantm factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT williamstrent factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT hordersophie factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT kritharidesleonard factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT vardyjanette factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT mandaliyahiren factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT nordmaninaic factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT lynamjames factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT bonaventuratony factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab AT sverdlovaaronl factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab |